Sobi and Innate Pharma License Lacutamab in T-Cell Lymphoma
August 11, 2026
August 11, 2026
PALO ALTO, California, Aug. 11 -- Cooley, a law firm, issued the following news release:
* * *
Sobi and Innate Pharma License Lacutamab in T-Cell Lymphoma
Cooley advised Swedish Orphan Biovitrum AB (publ) (Sobi(R)) on its strategic partnership with Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate) to enable initiation of the TELLOMAK-3 confirmatory phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approv . . .
* * *
Sobi and Innate Pharma License Lacutamab in T-Cell Lymphoma
Cooley advised Swedish Orphan Biovitrum AB (publ) (Sobi(R)) on its strategic partnership with Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate) to enable initiation of the TELLOMAK-3 confirmatory phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approv . . .